Results 181 to 190 of about 27,037 (216)

Daptomycin for the treatment of acute bacterial meningitis: a narrative review.

International Journal of Antimicrobial Agents, 2023
BACKGROUND There is a growing interest in the utilization of daptomycin for the treatment of multi-drug resistant, Gram-positive infections. Pharmacokinetic studies suggest that daptomycin could penetrate into the cerebrospinal fluid, albeit to a small ...
Rami H. Jaber, Nathan P. Beahm
semanticscholar   +1 more source

Daptomycin

Reactions Weekly, 2020
semanticscholar   +4 more sources

Daptomycin

Drugs, 2004
Daptomycin is a lipopeptide antibacterial with rapid in vitro activity against Gram-positive cocci. It is approved for use in patients with complicated skin and skin structure infections (cSSSIs) caused by specified Gram-positive cocci. In vitro, daptomycin was active against Staphylococcus aureus (including meticillin-resistant strains), Streptococcus
Caroline, Fenton, Gillian M, Keating, Monique P, Curran   +2 more
openaire   +4 more sources

Daptomycin

Reactions Weekly, 2018
Daptomycin is a cyclic lipopeptide antibiotic used for the treatment of Gram-positive infections including complicated skin and skin structure infections, right-sided infective endocarditis, bacteraemia, meningitis, sepsis and urinary tract infections ...
Heidary, M., Goudarzi, M., Soleimani, S., Khosravi, A.D., Khoshnood, S., Nasiri, M.J.   +5 more
openaire   +2 more sources

Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper

Clinical Microbiology and Infection, 2020
SCOPE This position paper describes the view adopted by EUCAST on the role of daptomycin in the treatment of serious infections caused by Enterococcus species.
G Kahlmeter, Rafael Canton, A P Macgowan   +2 more
exaly   +2 more sources

Daptomycin

Journal of Infection, 2007
There has been a steady rise in the prevalence of resistant Gram-positive pathogens and concerns about the clinical effectiveness of glycopeptides in treating infections due to Staphylococcus aureus. Daptomycin is a novel lipopeptide antimicrobial agent with activity against Gram-positive organisms, including multi-resistant strains.
David A, Enoch, Jeanine M, Bygott, Marie-Louise, Daly, J Andreas, Karas   +3 more
openaire   +3 more sources

Daptomycin, its membrane-active mechanism vs. that of other antimicrobial peptides.

Biochimica et Biophysica Acta - Biomembranes, 2020
Over 3000 membrane-active antimicrobial peptides (AMPs) have been discovered, but only three of them have been approved by the U.S. Food and Drug Administration (FDA) for therapeutic applications, i.e., gramicidin, daptomycin and colistin.
Huey W. Huang
semanticscholar   +1 more source